Protica Bio * https://www.protica.bio

* Olga Nissan

* Biotech/Pharma* • Liquid biopsy & Diagnostics:

Getting closer to transforming early detection and disease management

o Executive Summary Protica Bio is at the forefront of transforming cancer diagnostics by integrating proteomics and AI to identify immunotherapy response signatures using FFPEs-stable tissue biopsies used to diagnose cancer. Our novel approach enables the detection of an unprecedented number of 11,000 tumorspecific proteins, significantly minimizing the noise from other tissues. The cancer predictive diagnostic market reached $16 billion and is poised for growth to $80 billion with a 26% CAGR until 2030. We are finalizing a clinical study involving 120 anti-PD-1 treated- Head and Neck cancer patients, which is yielding an exciting signature that will likely lead to novel anti-PD1 therapeutic combinations.

o Core Technology Originating from the groundbreaking work of Prof. Tamar Geiger, Protica Bio's technology leverages advanced proteomics, enhanced by AI, to analyze 11,000 proteins per sample, encompassing even those of low abundance. This capability far exceeds the approximately reported 5,000 proteins for FFPEs. Such extensive coverage facilitates the identification of novel biomarkers by analyzing their expression in tumors, thereby enhancing patient treatment. Moreover, the technology uncovers the MoA behind treatment responses. These insights allow us to suggest treatments that can markedly enhance patient outcomes.

o Product Profile We focus on predicting response to immunotherapy and suggesting solutions for anti-PD-1 resistant tumors. We are conducting clinical trials and producing robust and promising results. We are in collaboration discussions with top medical centers in the US and leading pharmaceutical companies. o Business Strategy We offer sophisticated clinical assessments, patient stratification, and data-driven drug treatment choices. We're gearing up to collaborate with pharmaceutical firms to discover biomarkers for ICI therapies at various stages, from experimental to clinical trials. Our diagnostic services are set for reimbursement.

o What's Next? We are focused on validating key biomarkers and creating companion diagnostic tools for practical clinical application. Additionally, we are preparing to launch a Seed round to facilitate further development and GTM strategy with the goal of launching a diagnostic service in the US by Q1 2026. Over the next two years, we anticipate significant growth, including establishing a CLIA-certified laboratory, forging major strategic partnerships and clinical trials, and incorporating additional indications into our pipeline.